In 2023, the systemic hormonal preparations sales (excluding sex hormones and insulins) in the UK were the baseline for forecasts, showing a consistent upward trend through 2028. Forecasts predict sales will grow from 519.76 million pounds in 2024 to 538.61 million pounds in 2028, marking a steady increase. The growth reflects a year-on-year percentage increase, indicating the sector's stability with compound annual growth rate observed over five years.
Future trends to watch for include:
- Potential impacts of regulatory changes on market dynamics.
- Advancements in hormonal therapy technologies and new product launches.
- Healthcare policy reforms possibly affecting market growth.
